

APPLIED GENETIC TECHNOLOGIES CORP  
Form 8-K/A  
August 02, 2018

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K/A**

**(Amendment No. 1)**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): July 25, 2018**

**APPLIED GENETIC TECHNOLOGIES CORPORATION**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-36370**  
**(Commission**

**File Number)**  
**14193 NW 119<sup>th</sup> Terrace**

**59-3553710**  
**(IRS Employer**

**Identification Number)**

**Suite 10**

**Alachua, Florida, 32165**

**(Address of principal executive offices) (Zip Code)**

**(386) 462-2204**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Explanatory Note**

This Current Report on Form 8-K/A is being filed as an amendment to the Current Report on Form 8-K filed by Applied Genetic Technologies Corporation on July 31, 2018 (the "Original Filing"). The sole purpose of this amendment is to correct a scrivener's error relating to Mr. Sullivan's salary change for fiscal year 2019. All other matters discussed in the Original Filing remain unchanged.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On July 25, 2018, the compensation committee of our board of directors approved bonus payments for fiscal year 2018 and salary changes for fiscal year 2019 for Susan Washer, our president and chief executive officer, Mark Shearman, our chief scientific officer, William Sullivan, our chief financial officer, Stephen Potter, our vice president and chief business officer, and Andrew Ashe, our general counsel. The following table sets forth for each individual the amount of their bonus for fiscal year 2018 and their salary for fiscal year 2019.

<b>Name</b>	<b>Fiscal Year 2018 Bonus</b>	<b>Fiscal Year 2019 Salary</b>
Susan Washer	\$ 200,000.00	\$ 514,150.00
Mark Shearman	\$ 136,000.00	\$ 402,097.00
William Sullivan	\$ 120,000.00	\$ 351,900.00
Stephen Potter	\$ 110,000.00	\$ 352,862.00
Andrew Ashe	\$ 108,290.00	\$ 340,000.00

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**APPLIED GENETIC TECHNOLOGIES  
CORPORATION**

By: /s/ Andrew Ashe  
Andrew Ashe  
General Counsel

Date: August 1, 2018